Progress of leukemia with NUTM1 gene rearrangement

VernacularTitle:NUTM1基因重排白血病的研究进展
Author: Yijing JIN ¹ ; Shaomin YANG ; Zifen GAO
Author Information

1. 北京大学医学部18级临床一班，北京　100032
Keywords: Hematological malignancies; Molecular typing; NUTM1; Gene rearrangement; Prognosis
From: Journal of Leukemia & Lymphoma 2022;31(10):631-633
CountryChina
Language:Chinese
Abstract: Molecular typing of leukemia is the basis of risk assessment and treatment options. NUTM1 gene (15q14) rearrangement is a novel molecular type of acute B lymphoblastic leukemia (B-ALL), which is mainly found in children (≥1 year old) and infants (< 1 year old). The number of patients is slightly more in children than infants. However, in infantile ALL, NUTM1 rearrangement is the second most common molecular abnormality. These children respond well to conventional chemotherapy regimens and with a good prognosis. The number of leukemia patients with NUTM1 gene rearrangement is still small, and there is no relevant study or case report in China. NUT protein encoded by NUTM1 gene is a chromatin regulator, which is related to histone acetylation regulation and chromatin remodeling. This article aims to introduce the clinicopathological features, detection methods, possible tumorigenic mechanisms and therapeutic prospects of leukemia with NUTM1 gene rearrangement, to increase the understanding of this type of leukemia and provide reference for the precise molecular subtyping and treatment.